Dr. Hongyang Wang, a professor, chief physician and doctoral supervisor, currently serves as the director of National Center for Liver Cancer of China
Lecture Hall 206, 2th Floor of Building 6 of Science Laboratory Buildings
Precision medicine, as currently envisioned or being practised, will emerge as a viable option in years to come. Due to the heterogeneous nature of tumors, molecular profiling is crucial to our understanding of how genomics plays a role in the cause or development of an individual cancer. Such tumor profiles can subsequently be applied to exclusively tailor cancer therapies to directly target a causative mutation for a malignancy, ultimately achieving a personalized and precise approach to cancer treatment. This approach is termed precision oncology. Precision oncology has made progress in leaps and bounds in recent years and is currently at the heart of revolutionizing cancer research. However, emerging data suggest that a major refinement is needed in the theory and practice of precise oncology frameworks. There is no doubt that thoroughly understanding of the complex mechanism and systematically defining the cancers with innumerable molecular and epigenetic alterations are crucial to precision treatment. Integrated monitoring and analysis gene expression profiling, epigenetic profiling, proteomic profiling, immune and metabolism profile could provide a more comprehensive overview of an individual tumor. Meanwhile, efforts in precision oncology should be held to the bar of traditional medicine, and meaningful improvements in clinical outcomes ought to be tested in rigorous clinical trials. All the efforts and resources would help to accomplish precision medicine in a truly personalized manner.
Dr. Hongyang Wang, a professor, chief physician and doctoral supervisor, currently serves as the director of National Center for Liver Cancer of China, and the director of International Cooperation Laboratory on Signal Transduction in Eastern Hepatobiliary Surgery Hospital, Shanghai, China. Dr. Wang was selected as a member of Chinese Academy of Engineering in 2005 and as a member of the Academy of Sciences for the Developing World in 2011. In 2015, Dr. Wang set up the Chinese Society of Clinical Precision Medicine as chairman. In 2017, she was selected as vice president of the Chinese Anti-Cancer Association and Shanghai Medical Association.
Dr. Hongyang Wang focuses on molecular mechanisms and translational medicine research of tumors and made an important contribution to molecular mechanism of tumorigenesis, signaling network regulation of tumor, and liver cancer biomarkers finding. She has published more than 200 papers in the important international magazines such as Cancer Cell, Lancet Oncology, Gastroenterology, Hepatology, Cancer Research etc, with a total citation of 7000. She applied 48 innovation patents, and 17 of them have been warranted (3 international patents). Professor Wang also developed Glypican-3 detection kit for HCC diagnosis, and it is the first pathological detection kit for HCC with complete intellectual property in China issued by China Food & Drug Administration (CFDA). Dr. Wang has received a lot of honors, such as National Awards for Science and Technology Progress (Innovation Team Award), National Natural Science Award (Grade II), Shanghai Natural Science Award (Grade I), Shanghai Medical Science Technology Award (Grade I), Science and Technology Award of HO LEUNG HO LEE FOUNDATION, and Scientist and Engineer Award of Asia of the AMOREPACIFIC Award for Outstanding Women in Sciences.